跳到正文
原文
The Lancet Infectious Diseases· Frank Bähner, Saul N Faust, Leela R L Davies, Olga Blokhina, Donald M Brandon, William B Smith, Vengalil Krishna K Chatterjee, Hana Hassanin, Tara M Babu, Adam Zuiani, Susanne Steinhauser, Asaf Poran, Claire Brittain, Eric Mucker, Jay W Hooper, Robbert G van der Most, Pedro L Alonso, Özlem Türeci, Federico J Mensa, Uğur Şahin·· 2026-06-04AI 评分60

mRNA 猴痘疫苗候选 BNT166a 首次人体试验:安全性与免疫原性结果

[Articles] Safety and immunogenicity of mRNA-based mpox vaccine candidate BNT166a: an open-label, dose-escalation, first-in-human trial

AI 导读

mRNA 猴痘疫苗候选 BNT166a 的开放标签、剂量递增、首次人体试验显示,在 VACV 未感染和已感染参与者中耐受性良好,局部和全身反应原性事件在第二剂后比第一剂更常见。

来源:The Lancet Infectious Diseases · thelancet.com